论文部分内容阅读
目的探讨伊立替康联合雷替曲塞在晚期结直肠癌二线化疗中的疗效及安全性。方法回顾性分析2011年1月至2013年12月采取一线方案氟尿嘧啶联合奥沙利铂(FOLFOX)化疗失败后进行伊立替康联合雷替曲塞治疗的32例晚期结直肠癌患者的临床病例资料,并分析其临床效果、不良反应以及安全性。结果 32例患者病情部分缓解6例,稳定11例,进展13例,中位总生存时间为(13.2±1.1)个月,中位无进展生存时间为(3.7±0.2)个月,最常见的不良反应为疲倦、食欲降低以及中性粒细胞减少,发生率分别为71.9%和68.8%。结论雷替曲塞联合伊立替康对一线治疗失败的晚期结直肠癌患者具有较高的效果,且对不良反应均耐受,该方法值得推荐。
Objective To investigate the efficacy and safety of irinotecan combined with raltitrexed in second-line chemotherapy for advanced colorectal cancer. Methods The clinical data of 32 patients with advanced colorectal cancer treated with irinotecan and raltitrexed after first-line Fluorouracil plus oxaliplatin (FOLFOX) chemotherapy failure between January 2011 and December 2013 were retrospectively analyzed. , And analyzed its clinical effect, adverse reactions and safety. Results Sixteen patients were partially relieved, 11 were stable, and 13 were advanced. The median overall survival time was (13.2 ± 1.1) months and the median progression-free survival time was (3.7 ± 0.2) months. The most common Adverse reactions to fatigue, loss of appetite and neutropenia, the incidence was 71.9% and 68.8%. Conclusions Raltitrexed and irinotecan are highly effective in patients with advanced colorectal cancer who have failed first-line therapy and are refractory to adverse reactions. This approach is recommended.